(VIANEWS) – Ameresco (AMRC), Ship Finance International Limited (SFL), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ameresco (AMRC)
32.9% sales growth and 5.86% return on equity
Ameresco, Inc. provides comprehensive energy services for businesses and organizations in North America and Europe. It offers energy efficiency, infrastructure upgrades, energy security and resilience, asset sustainability, and renewable energy solutions. The company operates through U.S. Regions, U.S. Federal, Canada, and Non-Solar Distributed Generation segments. It designs, develops, engineers, and installs projects that reduce the energy, as well as operations and maintenance costs of customers' facilities. The company's projects primarily include various measures customized for the facility and designed to enhance the efficiency of building systems, such as heating, ventilation, cooling, and lighting systems. It also offers renewable energy products and services, such as the construction of small-scale plants for customers that produce electricity, gas, heat, or cooling from renewable sources of energy; and sells electricity and processed renewable gas fuel, heat, or cooling. In addition, the company provides integrated- photovoltaic (PV) and consulting, and enterprise energy management services; sells solar PV energy products and systems; and owns and operates a wind power project located in County Kerry, Ireland. It serves federal, state, and local governments, as well as healthcare and educational institutions, housing authorities, and commercial and industrial customers. As of December 31, 2019, the company owned and operated 99 small-scale renewable energy plants and solar PV installations. Ameresco, Inc. was founded in 2000 and is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Ameresco has a trailing twelve months EPS of $1.09.
PE Ratio
Ameresco has a trailing twelve months price to earnings ratio of 23.85. Meaning, the purchaser of the share is investing $23.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.86%.
Sales Growth
Ameresco’s sales growth is 15.8% for the ongoing quarter and 32.9% for the next.
Moving Average
Ameresco’s worth is way below its 50-day moving average of $28.95 and under its 200-day moving average of $27.76.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 66.7% and 22.5%, respectively.
2. Ship Finance International Limited (SFL)
24.4% sales growth and 11.6% return on equity
SFL Corporation Ltd., a maritime and offshore asset owning and chartering company, engages in the ownership, operation, and chartering out of vessels and offshore related assets on medium and long-term charters. The company operates in various sectors of the maritime, and shipping and offshore industries, including oil transportation, dry bulk shipments, chemical transportation, oil products transportation, container transportation, car transportation, and drilling rigs. As of December 31, 2023, the company owned seven crude oil carriers, six oil product tankers, 15 dry bulk carriers, 32 container vessels, one jack-up drilling rig, one ultra-deepwater drilling rig, and five car carriers. It primarily operates in Bermuda, Canada, Cyprus, Liberia, Namibia, Norway, Singapore, the United Kingdom, and the Marshall Islands. The company was formerly known as Ship Finance International Limited and changed its name to SFL Corporation Ltd. in September 2019. SFL Corporation Ltd. was founded in 2003 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Ship Finance International Limited has a trailing twelve months EPS of $0.97.
PE Ratio
Ship Finance International Limited has a trailing twelve months price to earnings ratio of 14.05. Meaning, the purchaser of the share is investing $14.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.6%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 24, 2024, the estimated forward annual dividend rate is 1.08 and the estimated forward annual dividend yield is 7.69%.
Moving Average
Ship Finance International Limited’s worth is under its 50-day moving average of $13.80 and way above its 200-day moving average of $12.38.
3. Catalyst Pharmaceuticals (CPRX)
20.4% sales growth and 14.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.55%.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $15.22 at 20:22 EST, way under its 52-week high of $17.50 and way above its 52-week low of $11.55.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 21.2% and positive 203.4% for the next.
Moving Average
Catalyst Pharmaceuticals’s worth is below its 50-day moving average of $15.70 and higher than its 200-day moving average of $14.75.
4. PNM Resources (PNM)
9.7% sales growth and 4.11% return on equity
PNM Resources, Inc., through its subsidiaries, provides electricity and electric services in the United States. It operates through Public Service Company of New Mexico (PNM) and Texas-New Mexico Power Company (TNMP) segments. The PNM segment engages in the generation, transmission, and distribution of electricity. The segment owns and leases communication, office and other equipment, office space, vehicles, and real estate. It generates electricity using coal, natural gas and oil, nuclear fuel, solar, wind, and geothermal energy sources. The TNMP segment provides regulated transmission and distribution services. The segment also owns and leases vehicles, service facilities, and office locations throughout its service territory. The company serves residential, commercial, and industrial customers and end-users of electricity in New Mexico and Texas. PNM Resources, Inc. was founded in 1882 and is headquartered in Albuquerque, New Mexico.
Earnings Per Share
As for profitability, PNM Resources has a trailing twelve months EPS of $0.9.
PE Ratio
PNM Resources has a trailing twelve months price to earnings ratio of 40.14. Meaning, the purchaser of the share is investing $40.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.11%.
Yearly Top and Bottom Value
PNM Resources’s stock is valued at $36.13 at 20:22 EST, way below its 52-week high of $45.94 and above its 52-week low of $34.63.
5. RadNet (RDNT)
8.6% sales growth and 6.37% return on equity
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, RadNet has a trailing twelve months EPS of $0.37.
PE Ratio
RadNet has a trailing twelve months price to earnings ratio of 161.73. Meaning, the purchaser of the share is investing $161.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.37%.
